They spent their entire lives being treated like a punchline, being neglected, treated like the other, even from sometimes their own doctors, their own family members. Bonello founded the GLP-1 Collective in January, shortly after the FDA first removed tirzepatide from the shortage list, signaling that the national supply had stabilized
Development and characterization of mucoadhesive chitosan films for ophthalmic delivery of cyclosporine A
Additionally, because low NAD+ is linked to aging, its decline could contribute to the development of various age-related health concerns, including cardiovascular disease, metabolic disorders, the development of neurodegenerative diseases such as Alzheimers and Parkinsons, and cancer
Targeted Treatments Peptides can be designed to address specific skin concerns, from hydration to inflammation
Month 4 through month 6: the transformation deepens Months four through six represent the heart of the GLP-1 transformation
FDA approval is expected in 2027 or 2028